These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83. Tuberculosis: Drug discovery goes au naturel. Barry CE Nature; 2014 Feb; 506(7489):436-7. PubMed ID: 24572417 [No Abstract] [Full Text] [Related]
84. Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux. Lee RE; Hurdle JG; Liu J; Bruhn DF; Matt T; Scherman MS; Vaddady PK; Zheng Z; Qi J; Akbergenov R; Das S; Madhura DB; Rathi C; Trivedi A; Villellas C; Lee RB; Rakesh ; Waidyarachchi SL; Sun D; McNeil MR; Ainsa JA; Boshoff HI; Gonzalez-Juarrero M; Meibohm B; Böttger EC; Lenaerts AJ Nat Med; 2014 Feb; 20(2):152-158. PubMed ID: 24464186 [TBL] [Abstract][Full Text] [Related]
85. Drug-resistant tuberculosis: what do we do now? Telenti A; Iseman M Drugs; 2000 Feb; 59(2):171-9. PubMed ID: 10730543 [TBL] [Abstract][Full Text] [Related]
86. Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm. Chakraborty S; Rhee KY Cold Spring Harb Perspect Med; 2015 Apr; 5(8):a021147. PubMed ID: 25877396 [TBL] [Abstract][Full Text] [Related]
87. Letting the genome out of the bottle: prospects for new drug development. Young D Ann N Y Acad Sci; 2001 Dec; 953():146-50. PubMed ID: 11795407 [TBL] [Abstract][Full Text] [Related]
88. [Molecular mechanisms of the formation of drug resistance of Mycobacterium tuberculosis (review of the literature)]. Tungusova OS; Mar'iandyshev AO Probl Tuberk; 2001; (6):48-9. PubMed ID: 11641963 [No Abstract] [Full Text] [Related]
89. Current pharmaceutical design of antituberculosis drugs: future perspectives. Speck-Planche A; Scotti MT; de Paulo-Emerenciano V Curr Pharm Des; 2010; 16(24):2656-65. PubMed ID: 20642433 [TBL] [Abstract][Full Text] [Related]
90. New treatment options for multidrug-resistant tuberculosis. Field SK; Fisher D; Jarand JM; Cowie RL Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676 [TBL] [Abstract][Full Text] [Related]
91. [Shorter treatment of pulmonary tuberculosis is only acceptable with at least 4 drugs in the initial combination of tuberculostatic agents]. Veen J Ned Tijdschr Geneeskd; 1996 Nov; 140(44):2164-7. PubMed ID: 8984351 [No Abstract] [Full Text] [Related]
93. [The problems in the chemotherapy of tuberculosis taking into account new data on its causative organism]. Egorov AM; Sazykin IuO Antibiot Khimioter; 2000; 45(5):3-5. PubMed ID: 10862346 [No Abstract] [Full Text] [Related]
94. [Multidrug-resistant tuberculosis: current epidemiology, therapeutic regimens, new drugs]. Gómez-Ayerbe C; Vivancos MJ; Moreno S Rev Esp Quimioter; 2016 Sep; 29 Suppl 1():35-8. PubMed ID: 27608311 [TBL] [Abstract][Full Text] [Related]
95. Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015. Zhang Y; Yew WW Int J Tuberc Lung Dis; 2015 Nov; 19(11):1276-89. PubMed ID: 26467578 [TBL] [Abstract][Full Text] [Related]
96. Spectinamides: a challenge, a proof, and a suggestion. Viveiros M; Pieroni M Trends Microbiol; 2014 Apr; 22(4):170-1. PubMed ID: 24636244 [TBL] [Abstract][Full Text] [Related]